Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

Lynnette Fernandez-Cuesta1 and Roman K. Thomas2

Abstract

The four members of the ERBB (HER) family of transmembrane receptor tyrosine kinases are frequently activated in cancer by several mechanisms, such as mutation, amplification, or autocrine ligand–receptor stimulation. We recently identified gene fusions involving the ERBB ligand gene, NRG1, which represent a novel mechanism for ERBB pathway deregulation. These fusions lead to expression and presentation of the EGF-like domain of NRG1 on the cell surface, which binds to ERBB3 in an autocrine and juxtacrine manner, thus inducing the formation of ERBB2–ERBB3 heterodimers, and subsequent activation of the PI3K–AKT and MAPK signaling pathways. These fusion genes were exclusively detected in lung adenocarcinomas of never smokers of the invasive mucinous subtype, which usually presents as a multifocal and unresectable disease, for which no effective treatment exists. Considering the large amount of drugs that target ERBB2 (HER2) and ERBB3 (HER3), and which are currently in different stages of clinical development, detecting and targeting NRG1 fusions in invasive mucinous lung adenocarcinomas may represent a therapeutic opportunity for this aggressive disease. Clin Cancer Res; 21(9); 1989–94. ©2014 AACR.

Background

ERBB1 (EGFR; ref. 1), ERBB2 (HER2; ref. 2), ERBB3 (3, 4), and ERBB4 (5) constitute the ERBB family of transmembrane receptor tyrosine kinases (RTK). These RTKs are composed of a large extracellular ligand-binding domain, a transmembrane domain, a small intracellular juxtamembrane domain, a kinase domain, and a C-terminal tail (6). Upon ligand binding, these receptors form hetero- or homodimers, which induce the phosphorylation of their intrinsic kinase domain, resulting in the activation of the downstream PI3K–AKT and MAPK pathways (7–9). There are 13 polypeptide extracellular ligands for these RTK, all of them carrying an EGF-like consensus sequence, consisting of six cysteine residues. These ligands can be subdivided in those that specifically bind EGFR and ERBB4 (such as EGF, TGF-α, amphiregulin, epiregulin, BTC, HB-EGF, and EPR), and the neuregulins (NRG), which bind to ERBB3 (NRG1 and NRG4) and to ERBB4 (NRG1–NRG4; ref. 10). ERBB receptors are expressed in many cells of the epithelial, mesenchymal, and neuronal lineages, in which they have diverse roles in development, proliferation, and differentiation (11). Aberrant tyrosine kinase activity of ERBB receptors owing to gene amplification and mutations (EGFR and ERBB2; refs. 12–14), or autocrine ligand–receptor stimulation (10) can result in growth stimulation and tumorigenesis in various tumor types, including cancers of the breast, lung, brain, head and neck, and colon (12).

Contrary to ERBB1 and ERBB4, ERBB2 and ERBB3 are nonautonomous receptors and therefore their activation relies on their heterodimerization with other ERBB receptors: ERBB2 lacks the capacity to interact with growth factor ligands (15) but is the preferred dimerization partner of the other three receptors (16). ERBB3 is generally considered to be kinase deficient (17), although it has a low level of kinase activity (1,000-fold less than EGFR; refs. 18, 19). Interestingly, the heterodimer ERBB2–ERBB3 is considered the most transforming and mitogenic one (20–22), as suggested by the following: first, ERBB2-containing heterodimers undergo slow endocytosis, recycling more frequently back to the cell surface (23–25). Similarly, upon ligand binding and heterodimerization, ERBB3 undergoes tyrosine phosphorylation and can recruit PI3K but not GRB2, enabling ERBB3 to evade ligand-induced degradation (23, 26); and second, ERBB2–ERBB3 leads to the activation of both the PI3K–AKT and the MAPK pathways, strongly enhancing cellular proliferation and evasion of apoptosis (20, 21).

Because the main ligands for ERBB3 are NRGs, these molecules also activate ERBB2–ERBB3 heterodimers. In fact, coexpression of ERBB2 and ERBB3 constitutes a high-affinity receptor for these ligands (27). NRGs are signaling proteins mainly expressed in the nervous system, the heart, and the breast (28). They comprise a large family of growth factors that induce dimerization and activation of ERBB receptors (29). NRGs are encoded by four individual genes (NRG1–4), of which NRG1 is the best characterized. NRG1 generates six types of proteins (I–VI), and at least 31 isoforms (29). All of these isoforms have an extracellular EGF-like domain that induces activation of ERBB RTKs. Contrary to most NRG1 isoforms that undergo proteolytic cleavage resulting in the release of the EGF-like domain, type III NRG1s have a membrane-tethered EGF-like domain that restricts the signaling to cell–cell interactions mainly, although a small amount of the EGF-like domain of these isoforms has been found secreted into the medium (30).
ERBB3 is not frequently affected by mutation or amplification in cancer (14); in contrast, overproduction of ligands is another mechanism by which cancers aberrantly activate ERBB receptors. Several examples point toward the existence of an autocrine loop between ERBB3 and NRG1: in ovarian tumors that overexpressed NRG1 and ERBB3, inactivation of ERBB3 suppressed cancer...
growth in laboratory models (31). Similarly, an NRG1-mediated autocrine loop inducing ERBB3 activation was also discovered in head and neck cancer cells lacking ERBB2 amplification, and these cells were particularly sensitive to the EGFR/ERBB2 kinase inhibitor, lapatinib (32). Finally, analyses of prostate cancer cells and tumors suggest the existence of a paracrine loop involving NRG1 and the ERBB2–ERBB3 heterodimer (33).

We recently discovered recurrent CD74–NRG1 gene fusions, which result in the expression of the NRG1 III–β3 isoform in the otherwise NRG1-negative invasive mucinous subtype of lung adenocarcinomas (34). CD74–NRG1 activates ERBB3 as well as PI3K–AKT signaling (34), thus promoting anchorage-independently growth of NIH-3T3 cells (ref. 35; Fig. 1). Furthermore, NRG1 fusion-mediated signaling could be suppressed by clinically approved kinase inhibitors (35). NRG1 fusions are preferentially found in women who had never smoked, and whose tumors are negative for other known mutant oncogenic gene mutations such as those in KRAS [frequently mutated in invasive mucinous adenocarcinoma (IMA)], or EGFR (34, 35). In another study, CD74–NRG1-positive tumors displayed uncommon radiologic features in comparison with what it is usually seen in IMA (36).

Clinical-Translational Advances

Invasive mucinous adenocarcinoma accounts for 2% to 10% of all lung adenocarcinomas and is associated with an unfavorable clinical course because it usually presents as multifocal unresectable disease, for which no effective treatment exists (37–40). KRAS mutations were, until recently, the only recurrent oncogenic mutations identified in IMA, with a frequency ranging from 50% in Asians to 80% in Caucasians. NRG1 fusions are the first potentially treatable oncogenic driver alteration associated with a specific lung adenocarcinoma subtype and in contrary to KRAS mutations, which are associated with tobacco use, NRG1 fusions occur in KRAS-negative IMA of never smokers. Taking all together, the discovery of recurrent, oncogenic, and possibly targetable NRG1 fusions may represent a therapeutic opportunity for these tumors (34, 35).

Because NRG1 fusions act through activation of ERBB2–ERBB3 heterodimers (34), blocking the activity of these receptors may be the best strategy to treat NRG1-rearranged tumors. Similar to EGFR and ERBB4, the extracellular domain of ERBB3 probably exists in two different conformations: a tethered autoinhibited form and an un tethered ligand-bound form (41). In contrast, the crystal structure of ERBB2 reveals a constitutively activated conformation similar to that of ligand-bound EGFR. Although more mechanistic details exist for ERBB2 than for ERBB3 (14), and therefore more drugs are available for the former, blocking only this receptor might not be enough to completely shut down the signaling elicited by ERBB2–ERBB3. In fact, the effect of single-agent lapatinib or afatinib (irreversible small-molecule inhibitor of the ERBB2 and EGFR tyrosine kinases; ref. 42) has already been tested for NRG1 fusions in vitro, and downstream signaling was not completely shut down, although an inhibitory effect was observed (35). Reactivation of ERBB3 has been observed as a resistance mechanism to EGFR and ERBB2 inhibitors (31, 43–49), and such mechanism might help NRG1-rearranged tumor cells escape exclusive targeting of ERBB2. A more successful approach could be to

<table>
<thead>
<tr>
<th>Name (antibody)</th>
<th>Target</th>
<th>Biologic effect</th>
<th>Clinical status</th>
</tr>
</thead>
<tbody>
<tr>
<td>MM-121 (SAR256212)</td>
<td>ERBB3</td>
<td>In combination with cetuximab, it blocks reactivation of ERBB3 in mice EGFR T790M-L858R, resulting in a sustained and durable response (31, 55, 56)</td>
<td>Completed phase I and phase II studies ongoing</td>
</tr>
<tr>
<td>MM-111</td>
<td>ERBB2 and ERBB3</td>
<td>Antitumor activity in preclinical models that are dependent on ERBB2 overexpression (57)</td>
<td>Completed phase I safety and dose-finding trial</td>
</tr>
<tr>
<td>MM-141</td>
<td>IGF-IR and ERBB3</td>
<td>Prevents PI3K/AKT/mTOR network adaptation by blocking the redundant survival pathways and degrading the RTK complexes (58)</td>
<td>Ongoing phase I study to establish the recommended dose and schedule</td>
</tr>
<tr>
<td>MEHD7945A</td>
<td>EGFR and ERBB3</td>
<td>It has superior antitumor activity against multiple tumor models compared with monospecific antibodies (59)</td>
<td>Completed phase I safety and dose-finding trial</td>
</tr>
<tr>
<td>LJM716</td>
<td>ERBB3</td>
<td>It inhibits ligand-induced and ligand-independent ERBB3 dimerization (60)</td>
<td>Completed phase I safety and dose-finding trial</td>
</tr>
<tr>
<td>RG7116 (RO5479599)</td>
<td>ERBB3</td>
<td>It inhibits xenograft tumor growth and downregulates cell surface ERBB3. Its efficacy is further enhanced in combination with anti-ERBB2 (pertuzumab) antibodies (61)</td>
<td>Completed phase I safety and dose-finding trial</td>
</tr>
<tr>
<td>U3-1287 (AMG 888, patritumab)</td>
<td>ERBB3</td>
<td>It blocks the upregulation of total and phosphorylated ERBB3 that follows treatment with lapatinib and trastuzumab, and enhances the antitumor action of the combination against trastuzumab-sensitive and -resistant cells (48)</td>
<td>Completed phase I safety and dose-finding trial</td>
</tr>
</tbody>
</table>

Refs 62–66

Refs 52, 53

Refs 67

Refs 69, 70

Ref. 71

Ref. 72

Several phase I and phase II studies ongoing

Several phase I studies ongoing

Several phase I, phase II, and phase III studies ongoing

Several phase I, phase II, and phase III studies ongoing

Several phase I studies ongoing

Several phase I and phase II studies ongoing

Several phase I studies ongoing

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial

Several phase I safety and dose-finding trial
block ERBB2–ERBB3 heterodimerization. In this context, ligand-induced ERBB2–ERBB3–PI3K complexes can be disrupted by pertuzumab (monoclonal antibody that recognizes an epitope in the heterodimerization domain II of ERBB2; ref. 50), whereas ligand-independent complexes might be dissociated by trastuzumab (51). However, it is important to note that the observed clinical efficacy of all therapeutic inhibitors against ERBB2 has been limited to breast cancer with overexpression of this gene (14).

Several ERBB3 inhibitors showing promising preclinical data are currently in different phases of clinical trials. A selection of those, for which substantial preclinical and clinical data exist, is presented in Table 1. Several of these are being tested in combination with ERBB2-targeting drugs in breast and gastric ERBB2-positive tumors (refs. 52, 53; Clinical trials: NCT01602406, NCT02167854, NCT01512199). However, although the outcome of these clinical trials will help gauge the benefit that dual ERBB2 and ERBB3 inhibition might have in cancer patients, a clinical trial in a selected cohort of NRG1 fusion–positive cases is necessary to determine the benefit for this specific group of patients. Finally, given the activation of the PI3K–AKT signaling pathway, its inhibition may represent another therapeutic strategy. Inhibitors targeting PI3K itself or AKT have been in clinical development for several years now. Unfortunately, identification of the right patient population is not as clear as anticipated from preclinical experiments (54). Thus, inhibition of the upstream ERBB family members, ERBB2 and ERBB3, might be more promising at this point.

**Disclosure of Potential Conflicts of Interest**  
L. Fernandez-Cuesta and R.K. Thomas are listed as coinventors of a patent pending on NRG1 fusions in lung cancer, which is owned by the University of Cologne. R.K. Thomas is a founder and shareholder of Blackfield AG/New Oncology; reports receiving commercial research grants from AstraZeneca, E0S, and Merck; and is a consultant/advisory board member for AstraZeneca, Bayer, Blackfield AG/New Oncology, Boehringer Ingelheim, Clovis Oncology, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, Puma, Roche, and Sanofi. No other potential conflicts of interest were disclosed.

**Authors’ Contributions**  
Conception and design: L. Fernandez-Cuesta, R.K. Thomas  
Development of methodology: L. Fernandez-Cuesta, R.K. Thomas  
Writing, review, and/or revision of the manuscript: L. Fernandez-Cuesta, R.K. Thomas  
Study supervision: L. Fernandez-Cuesta, R.K. Thomas

Received October 10, 2014; accepted November 19, 2014; published OnlineFirst December 11, 2014.

---

**References**


12. Fernandez-Cuesta and Thomas

---

**Clinical Cancer Research**  
1992 Clin Cancer Res; 29(1) May 1, 2015

---

**Disclosure of Potential Conflicts of Interest**  
L. Fernandez-Cuesta and R.K. Thomas are listed as coinventors of a patent pending on NRG1 fusions in lung cancer, which is owned by the University of Cologne. R.K. Thomas is a founder and shareholder of Blackfield AG/New Oncology; reports receiving commercial research grants from AstraZeneca, E0S, and Merck; and is a consultant/advisory board member for AstraZeneca, Bayer, Blackfield AG/New Oncology, Boehringer Ingelheim, Clovis Oncology, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, Puma, Roche, and Sanofi. No other potential conflicts of interest were disclosed.

**Authors’ Contributions**  
Conception and design: L. Fernandez-Cuesta, R.K. Thomas  
Development of methodology: L. Fernandez-Cuesta, R.K. Thomas  
Writing, review, and/or revision of the manuscript: L. Fernandez-Cuesta, R.K. Thomas  
Study supervision: L. Fernandez-Cuesta, R.K. Thomas

Received October 10, 2014; accepted November 19, 2014; published OnlineFirst December 11, 2014.
Targeting NRG1 Fusions
women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 587).


Molecular Pathways: Targeting *NRG1* Fusions in Lung Cancer

Lynnette Fernandez-Cuesta and Roman K. Thomas


Updated version

Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-0854

Cited articles

This article cites 68 articles, 31 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/9/1989.full.html#ref-list-1

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.